GNOM vs. SRVR
GNOM (Global X Genomics & Biotechnology ETF) and SRVR (Pacer Data & Infrastructure Real Estate ETF) are both exchange-traded funds - GNOM is a Health & Biotech Equities fund tracking the Solactive Genomics Index, while SRVR is a REIT fund tracking the FTSE Nareit All Equity REITs Index. Both are passively managed. Over the past 5 years, GNOM returned -8.97%/yr vs -3.37%/yr for SRVR. At a 0.48 correlation, their price movements are largely independent. GNOM charges 0.50%/yr vs 0.49%/yr for SRVR.
Performance
GNOM vs. SRVR - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GNOM achieves a 22.80% return, which is significantly higher than SRVR's 8.77% return.
GNOM
- 1D
- 0.28%
- 1M
- 14.03%
- 6M
- 16.77%
- YTD
- 22.80%
- 1Y
- 59.89%
- 3Y*
- 4.89%
- 5Y*
- -8.97%
- 10Y*
- —
SRVR
- 1D
- -0.36%
- 1M
- -8.32%
- 6M
- 3.46%
- YTD
- 8.77%
- 1Y
- -1.52%
- 3Y*
- 3.75%
- 5Y*
- -3.37%
- 10Y*
- —
GNOM vs. SRVR - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
GNOM Global X Genomics & Biotechnology ETF | 22.80% | 18.65% | -15.99% | -8.63% | -36.27% | -15.93% | 51.52% | 2.03% |
SRVR Pacer Data & Infrastructure Real Estate ETF | 8.77% | -1.99% | 2.70% | 6.84% | -31.90% | 22.31% | 11.99% | 15.27% |
Correlation
The correlation between GNOM and SRVR is 0.41, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.41 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.45 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.51 |
Correlation (All Time) Calculated using the full available price history since Apr 10, 2019 | 0.48 |
The correlation between GNOM and SRVR has been stable across timeframes, ranging from 0.41 to 0.51 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GNOM vs. SRVR — Risk / Return Rank
GNOM
SRVR
GNOM vs. SRVR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology ETF (GNOM) and Pacer Data & Infrastructure Real Estate ETF (SRVR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GNOM | SRVR | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.28 | ||
| Sortino ratioReturn per unit of downside risk | +2.99 | ||
| Omega ratioGain probability vs. loss probability | 1.34 | 1.00 | +0.34 |
| Calmar ratioReturn relative to maximum drawdown | 3.31 | -0.10 | +3.42 |
| Martin ratioReturn relative to average drawdown | 9.52 | -0.20 | +9.73 |
Loading charts...
Drawdowns
GNOM vs. SRVR - Drawdown Comparison
The maximum GNOM drawdown since its inception was -75.00%, which is greater than SRVR's maximum drawdown of -40.99%. Use the drawdown chart below to compare losses from any high point for GNOM and SRVR.
Loading charts...
Drawdown Indicators
| GNOM | SRVR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -75.00% | -40.99% | -34.01% |
Max Drawdown (1Y)Largest decline over 1 year | -18.17% | -14.78% | -3.39% |
Max Drawdown (3Y)Largest decline over 3 years | -44.24% | -18.34% | -25.90% |
Max Drawdown (5Y)Largest decline over 5 years | -72.14% | -40.99% | -31.15% |
Current DrawdownCurrent decline from peak | -49.25% | -20.35% | -28.90% |
Average DrawdownAverage peak-to-trough decline | -40.69% | -15.27% | -25.42% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.32% | 7.45% | -1.13% |
Volatility
GNOM vs. SRVR - Volatility Comparison
Global X Genomics & Biotechnology ETF (GNOM) has a higher volatility of 7.65% compared to Pacer Data & Infrastructure Real Estate ETF (SRVR) at 4.15%. This indicates that GNOM's price experiences larger fluctuations and is considered to be riskier than SRVR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GNOM | SRVR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.65% | 4.15% | +3.50% |
Volatility (6M)Calculated over the trailing 6-month period | 20.69% | 13.95% | +6.74% |
Volatility (1Y)Calculated over the trailing 1-year period | 27.49% | 17.24% | +10.25% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 33.70% | 19.84% | +13.86% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 34.14% | 21.41% | +12.73% |
GNOM vs. SRVR - Expense Ratio Comparison
GNOM has a 0.50% expense ratio, which is higher than SRVR's 0.49% expense ratio.
Dividends
GNOM vs. SRVR - Dividend Comparison
GNOM's dividend yield for the trailing twelve months is around 1.16%, less than SRVR's 2.81% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
GNOM Global X Genomics & Biotechnology ETF | 1.16% | 1.37% | 0.00% | 0.00% | 0.00% | 0.03% | 0.14% | 0.00% | 0.00% |
SRVR Pacer Data & Infrastructure Real Estate ETF | 2.81% | 2.67% | 2.00% | 3.69% | 1.70% | 1.19% | 1.59% | 1.61% | 2.13% |
Frequently Asked Questions
GNOM and SRVR have a correlation of 0.41, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GNOM has higher volatility (7.65%) compared to SRVR (4.15%). In terms of maximum drawdown, GNOM dropped -75.00% vs SRVR's -40.99%.
On 5-year performance, SRVR leads with -3.37% vs -8.97% for GNOM. On fees, SRVR is cheaper at 0.49% per year. On volatility, SRVR has been the lower-risk option at 4.15%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 5-year period, SRVR has performed better with a -3.37% return vs -8.97%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
SRVR is cheaper with a 0.49% expense ratio, compared with 0.50% for GNOM.
SRVR has the higher dividend yield at 2.81%, compared with 1.16% for GNOM.
GNOM is categorized as Health & Biotech Equities, while SRVR is REIT. GNOM tracks Solactive Genomics Index, while SRVR tracks FTSE Nareit All Equity REITs Index. They also come from different issuers: Global X and Pacer. Their fees differ too: 0.50% for GNOM and 0.49% for SRVR.
GNOM currently has the higher Sharpe Ratio (2.19 vs -0.09), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for GNOM and SRVR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer